| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.25B | -9.7% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | -40.1% |
| Gross margin | 32.8% | Net margin 13.1% |
| Revenue Q/Q | -21.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.17B | 67.2% |
| R&D | ¥0.01B | 3.4% |
| SG&A | ¥0.02B | 8.0% |
| Tax & other | ¥0.01B | 2.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验 ・ 南华仪器
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies